The system is intended for use in urgent care clinics, primary care settings, physician office laboratories, and pharmacies.

Ultra-fast point-of-care molecular diagnostics platform for key respiratory pathogens delivers results in under ten minutesCAMBRIDGE, United Kingdom, Feb. 16, 2026 (GLOBE NEWSWIRE) -- LEX Diagnostics, ...

LEX Diagnostics, a Cambridgeshire-based innovator in molecular diagnostics, has received U.S. Food and Drug Administration (FDA) 510(k) clearance and CLIA waived status for a platform that could ...

NEW YORK – Lex Diagnostics said on Monday that it has obtained 510 (k) clearance and CLIA waiver from the US Food and Drug Administration for its Velo point-of-care molecular diagnostic system and an ...

CAMBRIDGE, United Kingdom, July 18, 2023 (GLOBE NEWSWIRE) -- LEX Diagnostics (LEX) today announces the appointment of Dr Heather Danks as its Chief Technology Officer (CTO). The company is ...

The firm expects to acquire Lex Diagnostics when its Velo rapid PCR system is cleared by the FDA. The review has been ongoing since June.

QuidelOrtho Corporation (NASDAQ:QDEL) has announced a strategic pivot in its molecular diagnostics business, seeking to acquire full ownership of LEX Diagnostics following projected 510(k) FDA ...

LEX, which is based at Melbourn Science Park, was founded in 2020 as a spin-out from TTP Group. The FDA application for VELO was submitted in June 2025. The system supports multiplex testing for key ...

CAMBRIDGESHIRE, United Kingdom, June 06, 2025 (GLOBE NEWSWIRE) -- LEX Diagnostics, a leading innovator in molecular diagnostics, has submitted dual applications to the U.S. Food and Drug ...